Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$353.86M+9.5%-$390.98M+1.7%-$397.63M-2.0%-$389.92M-3.9%-$375.36M-0.9%
$12.93M+2.0%$12.68M+3.7%$12.23M-0.1%$12.25M+3.4%$11.85M-3.3%
$49.93M-18.9%$61.58M-23.7%$80.74M-19.1%$99.84M-13.5%$115.36M+5.2%
-$270.79M+10.5%-$302.41M+6.4%-$323.14M-6.5%-$303.41M+9.3%-$334.39M+5.3%
$34.23M+1.2%$33.84M+18.0%$28.68M+42.5%$20.13M+53.5%$13.11M+18.4%
$43.02M-9.4%$47.5M
$251.79M-16.3%$300.77M+21.8%$246.91M+23.0%$200.81M-41.0%$340.4M-12.9%
$37.43M+163%
-$305.02M+9.3%-$336.24M+4.4%-$351.82M-8.7%-$323.54M+6.9%-$347.5M+4.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Iovance Biotherapeutics, Inc. generate?
Iovance Biotherapeutics, Inc. (IOVA) generated -$270.8M in operating cash flow over the trailing twelve months.
What is Iovance Biotherapeutics, Inc.'s free cash flow?
After $34.2M of capital expenditures, Iovance Biotherapeutics, Inc.'s free cash flow was -$305.0M over the trailing twelve months, up 12.2% year over year.
Where does Iovance Biotherapeutics, Inc.'s cash flow data come from?
Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.